Original-Research: SynBiotic SE Faces Promising Growth

On September 17, 2024, NuWays AG released new research on SynBiotic SE, affirming a BUY recommendation with a target price of €12.40. The German company's ISIN is DE000A3E5A59. Henry Wendisch is the analyzing expert behind this report.

CEO Daniel Kruse has marked a year at SynBiotic SE. Regulatory changes in Germany, particularly the declassification of medical cannabis as a narcotic, have strongly influenced SynBiotic's financial outlook. SynBiotic is pursuing a Buy-and-Build strategy across European cannabis, hemp, and cannabinoid markets.

The company is positioned to benefit from dynamic market growth. Industrial hemp demand may quadruple by 2030, supported by regulatory adjustments. Medical cannabis demand could see a tenfold increase, bolstered by Germany's Cannabis Act.

By the end of FY2027, SynBiotic SE is projected to reach €40.8m in sales, largely driven by the medical cannabis segment. Additional growth is expected from further acquisitions. SynBiotic aims for break-even by FY2025, with cost-saving measures contributing significantly.